High PD-L1 expression in the tumor microenvironment (TME) has been correlated with response to PD-1/PD-L1 blockade therapy and is used as a biomarker for the initiation of immunotherapy in NSCLC (1, 4, 9). Here, CD274 is linked to neoplasm.